| Date | Title | Description |
| 10.06.2025 | Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME) | EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R
Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels
No Safety Issues Observed Following a Single Intravitreal (IVT) Injection
Multiple Ascending Dose Study Planned fo... |
| 30.04.2024 | Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific ... | SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal f... |
| 16.05.2023 | Eluminex Biosciences Receives Scientific Recognition for its Recombinant Human Collagen (rhCIII) Biosynthetic Cornea (EB-301) Program to Treat Corneal Blindness | Awarded Honors at the American Society of Cataract and Refractive Surgery (ASCRS) and the Association for Research in Vision and Ophthalmology (ARVO)
SUZHOU, China and SAN FRANCISCO, May 16, 2023 /PRNewswire/ -- Eluminex Biosciences (Elumin... |
| 28.02.2023 | Eluminex Biosciences Closes $40+ Million Series B Financing to Continue the Development of Innovative Ophthalmic Assets and Recombinant Human Collagen Technology | SUZHOU, China and SAN FRANCISCO, Feb. 28, 2023 /PRNewswire/ -- Eluminex Biosciences (Suzhou) Limited (Eluminex) officially announced today the closing of a Series B financing of over $40 million (USD). Financing was led by Cenova Capital wi... |
| 28.02.2023 | Eluminex Biosciences Closes $40+ M Series B Financing | Eluminex Biosciences, a Suzhou, China and San Francisco, CA-based biotechnology company focusing on ophthalmic diseases and recombinant human collagen technology, raised $40+ M in Series B funding.
The round was led by Cenova Capital with p... |
| 15.02.2023 | Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301) | Initial Part A results to be presented at the upcoming American Society of Cataract and Refractive Surgery Annual Meeting
EB-301 has the potential to be the world's first approved rhCIII biosynthetic corneal implant for the treatment of cor... |
| 19.01.2022 | Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings | Purchase of Assets and Related Global Commercialization Rights for Oral 9-cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness.
Clinical Stage Asset Has Potential for First Approved Oral Therapy for Leber's Congenital Amaurosis (LC... |
| 30.11.2020 | Eluminex Biosciences Closes $50M Series A Financing | Eluminex Biosciences Limited, a Shangai, China-based ophthalmic biotechnology company, completed a $50m (USD) Series A financing.
The round was co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan ... |
| - | Eluminex Biosciences | “Innovative Ocular Therapeutics for China and Global Markets About Eluminex Biosciences (Suzhou) Limited We are a clinical-stage biotechnology company focused on development and commercialization of innovative therapeutics to fulfill unmet ... |
